All Stories

  1. Data-driven subphenotyping uncovers ulcerative colitis subtype with high risk for relapse in Japan: a prospective multicenter cohort study

    Article • The Lancet Regional Health - Western Pacific, August 2026, Elsevier

    Taku Kobayashi

  2. Efficacy and safety of ozanimod in Japanese patients with moderately to severely active ulcerative colitis naive to immunomodulators or advanced therapies: post hoc analysis of the phase 2/3 J-True North s...

    Article • Intestinal Research, July 2026, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  3. Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a long-term follow-up of the randomized RIVETING trial

    Article • Crohn’s & Colitis 360, July 2026, Oxford University Press (OUP)

    Taku Kobayashi

  4. Acute Severe Ulcerative Colitis Patients From Asia Have Lower Colectomy Risk Than Patients From Australasia

    Article • Clinical Gastroenterology and Hepatology, July 2026, Elsevier

    Taku Kobayashi

  5. Distinct predictive factors for acute severe ulcerative colitis in East Asian and Western populations

    Article • Inflammatory Bowel Diseases, June 2026, Oxford University Press (OUP)

    Taku Kobayashi

  6. Utilizing intestinal ultrasound to assess treatment response in ulcerative colitis

    Article • Intestinal Research, June 2026, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  7. Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL‐23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease

    Article • Journal of Gastroenterology and Hepatology, May 2026, Wiley

    Taku Kobayashi

  8. Phenotype-driven management in ileocecal Crohn’s disease: a narrative review with a proposed research framework

    Article • Therapeutic Advances in Gastroenterology, May 2026, SAGE Publications

    Taku Kobayashi

  9. Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus

    Article • Journal of Crohn s and Colitis, May 2026, Oxford University Press (OUP)

    Taku Kobayashi

  10. Correction: Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study)

    Article • Journal of Gastroenterology, April 2026, Springer Science + Business Media

    Taku Kobayashi

  11. Diagnosis and Management of Upper Gastrointestinal Involvement in Adult Patients With Crohn’s Disease: A Systematic Review

    Article • Clinical Gastroenterology and Hepatology, April 2026, Elsevier

    Taku Kobayashi

  12. International Magnetic Resonance Imaging Consensus for Use in Luminal Crohn’s Disease Trials and Clinical Practice

    Article • Clinical Gastroenterology and Hepatology, April 2026, Elsevier

    Taku Kobayashi

  13. Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study

    Article • Inflammatory Bowel Diseases, March 2026, Oxford University Press (OUP)

    Taku Kobayashi

  14. Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis

    Article • Journal of Crohn s and Colitis, March 2026, Oxford University Press (OUP)

    Taku Kobayashi

  15. Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis

    Article • Clinical Gastroenterology and Hepatology, March 2026, Elsevier

    Taku Kobayashi

  16. Definitions, diagnosis, management, and outcomes of upper gastrointestinal Crohn's disease: an international, expert RAND/UCLA appropriateness study

    Article • The Lancet Gastroenterology & Hepatology, March 2026, Elsevier

    Taku Kobayashi

  17. Anti-Integrin αvβ6 Autoantibodies Predict Response and Treatment Persistence to Advanced Therapies in Ulcerative Colitis

    Article • Clinical and Translational Gastroenterology, February 2026, Wolters Kluwer Health

    Taku Kobayashi

  18. Janus Kinase Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study

    Article • Clinical Gastroenterology and Hepatology, February 2026, Elsevier

    Taku Kobayashi

  19. Beyond the mucosa: intestinal ultrasound for post-endoscopic healing risk stratification in ulcerative colitis

    Article • Journal of Crohn s and Colitis, January 2026, Oxford University Press (OUP)

    Taku Kobayashi

  20. Data-Driven Subphenotyping Uncovers Ulcerative Colitis Subtype With High Risk for Relapse in Japan

    Article • January 2026, Elsevier

    Taku Kobayashi

  21. Global Discrepancies in Inflammatory Bowel Disease Care Reflect Health Care Expenditure Per Capita

    Article • Gastroenterology, January 2026, Elsevier

    Taku Kobayashi

  22. Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age

    Article • Inflammatory Bowel Diseases, November 2025, Oxford University Press (OUP)

    Taku Kobayashi

  23. Management of Patients with Ulcerative Proctitis: A Global Survey

    Article • Digestive Diseases and Sciences, November 2025, Springer Science + Business Media

    Taku Kobayashi

  24. Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor α antibody

    Article • Intestinal Research, October 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  25. Mechanism of IL-10 production via IL-1R in gut macrophages

    Article • Biochemical and Biophysical Research Communications, October 2025, Elsevier

    Taku Kobayashi

  26. Inadequate Efficacy of Biologics for Treating Proximal Ileal Lesions in Crohn’s Disease: A Prospective Multicenter Study

    Article • Clinical Gastroenterology and Hepatology, October 2025, Elsevier

    Taku Kobayashi

  27. Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study)

    Article • Journal of Gastroenterology, September 2025, Springer Science + Business Media

    Taku Kobayashi

  28. An Early Phase 2 Double-Blind, Placebo-Controlled Study of E6011, a Novel Anti-Fractalkine Antibody, in Patients with Crohn’s Disease

    Article • Inflammatory Intestinal Diseases, September 2025, Karger Publishers

    Taku Kobayashi

  29. International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials

    Article • Journal of Crohn s and Colitis, September 2025, Oxford University Press (OUP)

    Taku Kobayashi

  30. Early reduction in rectal wall thickness on transperineal ultrasound predicts mucosal healing in ulcerative colitis

    Article • Journal of Crohn s and Colitis, August 2025, Oxford University Press (OUP)

    Taku Kobayashi

  31. Asia Pacific association of gastroenterology consensus statements on histopathological evaluation of inflammatory bowel diseases

    Article • Therapeutic Advances in Gastroenterology, August 2025, SAGE Publications

    Taku Kobayashi

  32. Patient preferences for advanced therapies in ulcerative colitis using conjoint analysis

    Article • Intestinal Research, July 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  33. Week 2 remission with vedolizumab as a predictor of long-term remission in patients with ulcerative colitis: a multicenter, retrospective, observational study

    Article • Intestinal Research, July 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  34. Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint

    Article • Journal of Crohn s and Colitis, July 2025, Oxford University Press (OUP)

    Taku Kobayashi

  35. Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints

    Article • Clinical Gastroenterology and Hepatology, July 2025, Elsevier

    Taku Kobayashi

  36. Editorial: Time to EXIT? When Less Is More in IBD Management

    Article • Alimentary Pharmacology & Therapeutics, June 2025, Wiley

    Taku Kobayashi

  37. The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study

    Article • Intestinal Research, June 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  38. Characteristic gene expression profile of intestinal mucosa early in life promotes bacterial colonization leading to healthy development of the intestinal environment

    Article • Scientific Reports, May 2025, Springer Science + Business Media

    Taku Kobayashi

  39. Real‐World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus < 70 Years With Ulcerative Colitis: Multicenter Retrospective Study

    Article • Journal of Gastroenterology and Hepatology, May 2025, Wiley

    Taku Kobayashi

  40. Lifestyle restrictions are associated with impaired quality of life but not reduction in relapse in ulcerative colitis

    Article • Intestinal Research, May 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  41. Withdrawal of antitumour necrosis factor in patients with inflammatory bowel disease in remission: a randomised placebo-controlled clinical trial of GETECCU

    Article • Gut, May 2025, BMJ

    Taku Kobayashi

  42. Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis

    Article • Journal of Crohn s and Colitis, May 2025, Oxford University Press (OUP)

    Taku Kobayashi

  43. Nationwide multicenter prospective study on the usefulness, safety, and acceptability of colon capsule endoscopy in Japan

    Article • Gastrointestinal Endoscopy, May 2025, Elsevier

    Taku Kobayashi

  44. Global evolution of inflammatory bowel disease across epidemiologic stages

    Article • Nature, April 2025, Springer Science + Business Media

    Eduard Brunet, Taku Kobayashi

  45. Early resolution of bowel urgency by budesonide foam enema results in improved quality of life in patients with ulcerative colitis: a multicenter prospective observational study

    Article • Intestinal Research, April 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  46. Real‐World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study

    Article • Alimentary Pharmacology & Therapeutics, April 2025, Wiley

    Taku Kobayashi

  47. Fecal Calprotectin and C-Reactive Protein Association With Histologic and Endoscopic Endpoints in Mirikizumab-Treated Patients With Ulcerative Colitis

    Article • Crohn’s & Colitis 360, April 2025, Oxford University Press (OUP)

    Taku Kobayashi

  48. Asymptomatic Wilson’s Disease Diagnosed during the Course of Ulcerative Colitis: A Case Report and Review

    Article • Inflammatory Intestinal Diseases, March 2025, Karger Publishers

    Taku Kobayashi

  49. Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn’s Disease: Results from the Japanese CONFIDE Study

    Article • Advances in Therapy, February 2025, Springer Science + Business Media

    Taku Kobayashi

  50. Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study

    Article • Intestinal Research, January 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  51. First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study

    Article • Journal of Gastroenterology, January 2025, Springer Science + Business Media

    Taku Kobayashi

  52. Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition

    Article • Intestinal Research, January 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  53. Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study

    Article • Intestinal Research, January 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  54. Editorial: Leucine‐Rich Alpha‐2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease: Its Potential in Early‐Stage Disease—Authors' Reply

    Article • Alimentary Pharmacology & Therapeutics, January 2025, Wiley

    Taku Kobayashi

  55. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

    Article • The Lancet, January 2025, Elsevier

    Professor Vladimir V Rafalskiy, Taku Kobayashi

  56. International Consensus on the Use of Intestinal Ultrasound in Inflammatory Bowel Disease Trials

    Article • January 2025, Elsevier

    Taku Kobayashi

  57. Leucine‐Rich Alpha‐2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease

    Article • Alimentary Pharmacology & Therapeutics, December 2024, Wiley

    Taku Kobayashi

  58. Involvement of Mediterranean fever gene mutations in colchicine-responsive enterocolitis: a retrospective cohort study

    Article • EBioMedicine, December 2024, Elsevier

    Assitant Professor Tadashi Hosoya, Taku Kobayashi

  59. Real‐World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort Study

    Article • United European Gastroenterology Journal, November 2024, Wiley

    Taku Kobayashi

  60. Early change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis

    Article • Intestinal Research, October 2024, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  61. Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

    Article • Inflammatory Bowel Diseases, October 2024, Oxford University Press (OUP)

    Taku Kobayashi

  62. Impact of Concomitant Prescriptions and Lifestyle Factors on the Initial Course of Newly Diagnosed Inflammatory Bowel Disease

    Article • Inflammatory Intestinal Diseases, October 2024, Karger Publishers

    Taku Kobayashi

  63. Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective

    Article • United European Gastroenterology Journal, October 2024, Wiley

    Taku Kobayashi

  64. Risankizumab for Ulcerative Colitis

    Article • JAMA, September 2024, American Medical Association (AMA)

    Professor Vladimir V Rafalskiy, Taku Kobayashi

  65. Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus

    Article • Digestive and Liver Disease, August 2024, Elsevier

    Taku Kobayashi

  66. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment

    Article • Journal of Crohn s and Colitis, June 2024, Oxford University Press (OUP)

    Taku Kobayashi

  67. ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment

    Article • Journal of Crohn s and Colitis, June 2024, Oxford University Press (OUP)

    Taku Kobayashi

  68. Correction: Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study

    Article • Journal of Gastroenterology, May 2024, Springer Science + Business Media

    Taku Kobayashi

  69. A case of cytomegalovirus esophagitis difficult to distinguish from Crohn’s disease exacerbation

    Article • Clinical Journal of Gastroenterology, May 2024, Springer Science + Business Media

    Taku Kobayashi

  70. Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies

    Article • Intestinal Research, April 2024, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  71. Editorial: Exploring the influence of diet on later‐onset ulcerative colitis—Are eggs and spicy foods the key factors in Asia?

    Article • Alimentary Pharmacology & Therapeutics, April 2024, Wiley

    Taku Kobayashi

  72. Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights

    Article • Alimentary Pharmacology & Therapeutics, March 2024, Wiley

    Taku Kobayashi

  73. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

    Article • Inflammatory Bowel Diseases, March 2024, Oxford University Press (OUP)

    Taku Kobayashi

  74. Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials

    Article • Expert Review of Gastroenterology & Hepatology, March 2024, Taylor & Francis

    Taku Kobayashi

  75. Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn’s disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies

    Article • European Journal of Gastroenterology & Hepatology, February 2024, Wolters Kluwer Health

    Taku Kobayashi

  76. Measurement of the intracellular active metabolites of thiopurine drugs to evaluate the enzymatic activity of nudix hydrolase 15 in human blood samples

    Article • Journal of Chromatography B, February 2024, Elsevier

    Taku Kobayashi

  77. Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria

    Article • Journal of Gastroenterology, January 2024, Springer Science + Business Media

    Taku Kobayashi

  78. Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials

    Article • Inflammatory Bowel Diseases, January 2024, Oxford University Press (OUP)

    Taku Kobayashi

  79. The Global Evolution of Inflammatory Bowel Disease across Four Epidemiologic Stages

    Article • January 2024, Springer Science + Business Media

    Taku Kobayashi

  80. Editorial: Extending upadacitinib induction dosing in ulcerative colitis‐A delicate balance of efficacy and safety

    Article • Alimentary Pharmacology & Therapeutics, January 2024, Wiley

    Taku Kobayashi

  81. Involvement of Mediterranean Fever Gene Mutations in Colchicine-Responsive Enterocolitis: A Retrospective Cohort Study

    Article • January 2024, Elsevier

    Taku Kobayashi

  82. Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis

    Article • Clinical Gastroenterology and Hepatology, January 2024, Elsevier

    Taku Kobayashi

  83. White Blood Cell Counts and Future Relapse in Ulcerative Colitis under Low-Dose Thiopurine Treatment in Real-World Practice: A 3-Year Japanese Multi-Center Retrospective Cohort Study

    Article • Inflammatory Intestinal Diseases, December 2023, Karger Publishers

    Taku Kobayashi

  84. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

    Article • Gastroenterology, December 2023, Elsevier

    Taku Kobayashi

  85. Single Nucleotide Polymorphisms of the MEFV Gene E148Q Are Highly Associated With Disease Phenotype in Crohn’s Disease

    Article • Inflammatory Bowel Diseases, November 2023, Oxford University Press (OUP)

    Taku Kobayashi

  86. Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis

    Article • Journal of Gastroenterology, October 2023, Springer Science + Business Media

    Taku Kobayashi

  87. Immunomodulators after the discontinuation of anti‐tumor necrosis factor‐alpha antibody treatment and relapse in ulcerative colitis: A multicenter cohort study

    Article • Journal of Gastroenterology and Hepatology, October 2023, Wiley

    Taku Kobayashi

  88. Artificial intelligence quantifying endoscopic severity of ulcerative colitis in gradation scale

    Article • Digestive Endoscopy, October 2023, Wiley

    Taku Kobayashi

  89. Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus

    Article • Journal of Clinical Medicine, October 2023, MDPI AG

    Taku Kobayashi

  90. Letter: Transperineal ultrasonography for ulcerative proctitis—Applicability in the pregnant population? Authors' reply

    Article • Alimentary Pharmacology & Therapeutics, September 2023, Wiley

    Taku Kobayashi

  91. Trajectory analyses to identify persistently low responders to COVID-19 vaccination in patients with inflammatory bowel disease: a prospective multicentre controlled study, J-COMBAT

    Article • Journal of Gastroenterology, August 2023, Springer Science + Business Media

    Taku Kobayashi

  92. Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus

    Article • Inflammatory Bowel Diseases, August 2023, Oxford University Press (OUP)

    Taku Kobayashi

  93. 5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis

    Article • Scientific Reports, July 2023, Springer Science + Business Media

    Taku Kobayashi

  94. Multicenter prospective registration study of efficacy and safety of capsule endoscopy in Crohn’s disease in Japan (SPREAD-J study)

    Article • Journal of Gastroenterology, July 2023, Springer Science + Business Media

    Taku Kobayashi

  95. Endoscopic Lesions of Postoperative Anastomotic Area in Patients With Crohn’s Disease in the Biologic Era: A Japanese Multi-Centre Nationwide Cohort Study

    Article • Journal of Crohn s and Colitis, July 2023, Oxford University Press (OUP)

    Taku Kobayashi

  96. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, June 2023, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, Taku Kobayashi

  97. Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study

    Article • Journal of Gastroenterology, June 2023, Springer Science + Business Media

    Taku Kobayashi

  98. Correction: Characteristics of adult patients newly diagnosed with Crohn’s disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn’s disease in Japan (iCREST-CD)

    Article • Journal of Gastroenterology, May 2023, Springer Science + Business Media

    Taku Kobayashi

  99. Performing colonoscopy before steroid induction is associated with shorter steroid use in patients with ulcerative colitis

    Article • Intestinal Research, April 2023, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  100. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes

    Article • Journal of Crohn s and Colitis, April 2023, Oxford University Press (OUP)

    Taku Kobayashi

  101. A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn’s Disease

    Article • Journal of Crohn s and Colitis, March 2023, Oxford University Press (OUP)

    Taku Kobayashi

  102. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan

    Article • PharmacoEconomics, March 2023, Springer Science + Business Media

    Taku Kobayashi

  103. Diagnosis and Clinical Features of Perianal Lesions in Newly Diagnosed Crohn’s Disease: Subgroup Analysis from Inception Cohort Registry Study of Patients with Crohn’s Disease (iCREST-CD)

    Article • Journal of Crohn s and Colitis, March 2023, Oxford University Press (OUP)

    Taku Kobayashi

  104. Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021

    Article • Journal of Gastroenterology, February 2023, Springer Science + Business Media

    Taku Kobayashi

  105. Reducing Health Anxiety in Patients With Inflammatory Bowel Disease Using Video Testimonials: Pilot Assessment of a Video Intervention

    Article • JMIR Formative Research, February 2023, JMIR Publications Inc.

    Taku Kobayashi

  106. iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis

    Article • Journal of Clinical Medicine, February 2023, MDPI AG

    Taku Kobayashi

  107. Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial

    Article • Intestinal Research, January 2023, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  108. Author Correction: Improving IBD outcomes in the era of many treatment options

    Article • Nature Reviews Gastroenterology & Hepatology, January 2023, Springer Science + Business Media

    Taku Kobayashi

  109. International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients

    Article • Medicina, January 2023, MDPI AG

    Taku Kobayashi

  110. Improving IBD outcomes in the era of many treatment options

    Article • Nature Reviews Gastroenterology & Hepatology, January 2023, Springer Science + Business Media

    Taku Kobayashi

  111. Optimal Use of Serum Leucine-Rich Alpha-2 Glycoprotein as a Biomarker for Small Bowel Lesions of Crohn’s Disease

    Article • Inflammatory Intestinal Diseases, January 2023, Karger Publishers

    Taku Kobayashi

  112. Final Analysis of COVID-19 Patients With Inflammatory Bowel Disease in Japan (J-COSMOS): A Multicenter Registry Cohort Study

    Article • Gastro Hep Advances, January 2023, Elsevier

    Taku Kobayashi

  113. Milan Ultrasound Criteria Predict Relapse of Ulcerative Colitis in Remission

    Article • Inflammatory Intestinal Diseases, January 2023, Karger Publishers

    Taku Kobayashi

  114. Evidence-Based Approach to the Discontinuation of Immunomodulators or Biologics in Inflammatory Bowel Disease

    Article • Digestion, November 2022, Karger Publishers

    Taku Kobayashi

  115. De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease

    Article • Gut and Liver, November 2022, The Editorial Office of Gut and Liver

    Taku Kobayashi

  116. Characteristics of adult patients newly diagnosed with Crohn’s disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn’s disease in Japan (iCREST-CD)

    Article • Journal of Gastroenterology, August 2022, Springer Science + Business Media

    Taku Kobayashi

  117. Optimal use of serum leucine-rich alpha-2 glycoprotein as a biomarker for small bowel lesions of Crohn's disease

    Article • August 2022, Research Square

    Taku Kobayashi

  118. Early phase partial Mayo score following golimumab treatment is associated with endoscopic improvement at 1-year in ulcerative colitis; A post hoc analysis of PURSUIT-J randomized controlled trial

    Article • Inflammatory Intestinal Diseases, August 2022, Karger Publishers

    Katsumasa Nagano, Taku Kobayashi

  119. Usefulness of colestimide for diarrhea in postoperative Crohn's disease

    Article • JGH Open, July 2022, Wiley

    Taku Kobayashi

  120. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    Article • The Lancet Gastroenterology & Hepatology, July 2022, Elsevier

    Taku Kobayashi

  121. Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease

    Article • Cochrane Database of Systematic Reviews, June 2022, Wiley

    Taku Kobayashi

  122. Hospital Senpai: A pilot for reducing health anxiety in inflammatory bowel disease patients using video testimonials (Preprint)

    Article • June 2022, JMIR Publications Inc.

    Taku Kobayashi

  123. Editorial: is older‐onset ulcerative colitis more severe or less aggressively managed? Authorsʼ reply

    Article • Alimentary Pharmacology & Therapeutics, April 2022, Wiley

    Taku Kobayashi

  124. Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis—an accurate early predictor of response to treatment. Authors' reply

    Article • Alimentary Pharmacology & Therapeutics, April 2022, Wiley

    Taku Kobayashi

  125. Lower effectiveness of intravenous steroid treatment for moderate‐to‐severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study

    Article • Alimentary Pharmacology & Therapeutics, March 2022, Wiley

    Taku Kobayashi

  126. Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis

    Article • Alimentary Pharmacology & Therapeutics, February 2022, Wiley

    Taku Kobayashi

  127. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials

    Article • Gastroenterology, February 2022, Elsevier

    Taku Kobayashi

  128. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives

    Article • The Lancet Gastroenterology & Hepatology, February 2022, Elsevier

    Taku Kobayashi

  129. Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS)

    Article • Journal of Gastroenterology, January 2022, Springer Science + Business Media

    Taku Kobayashi

  130. Lack of Increased Risk of Lymphoma with Thiopurine Therapy Regardless of Dose and Duration of Treatment in Japanese Patients with Inflammatory Bowel Diseases

    Article • Digestion, January 2022, Karger Publishers

    Taku Kobayashi

  131. OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study

    Article • Journal of Crohn s and Colitis, January 2022, Oxford University Press (OUP)

    Taku Kobayashi

  132. Validation of a claims‐based algorithm to identify cases of ulcerative colitis in Japan

    Article • Journal of Gastroenterology and Hepatology, November 2021, Wiley

    Taku Kobayashi

  133. Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis

    Article • Intestinal Research, October 2021, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  134. Development of algorithms for identifying patients with Crohn’s disease in the Japanese health insurance claims database

    Article • PLOS One, October 2021, PLOS

    Taku Kobayashi

  135. A nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in Japan

    Article • Journal of Gastroenterology, October 2021, Springer Science + Business Media

    Taku Kobayashi

  136. Safety and efficacy of the endoscopic delivery of capsule endoscopes in adult and pediatric patients: Multicenter Japanese study (AdvanCE‐J study)

    Article • Digestive Endoscopy, September 2021, Wiley

    Taku Kobayashi

  137. Increased DNA-incorporated thiopurine metabolite as a possible mechanism for leukocytopenia through cell apoptosis in inflammatory bowel disease patients with NUDT15 mutation

    Article • Journal of Gastroenterology, September 2021, Springer Science + Business Media

    Taku Kobayashi

  138. Endoscopic evaluation after surgery in inflammatory bowel disease – Authors' reply

    Article • The Lancet Gastroenterology & Hepatology, September 2021, Elsevier

    Taku Kobayashi

  139. Stringent criteria for withdrawal of biologics in ulcerative colitis – Authors' reply

    Article • The Lancet Gastroenterology & Hepatology, September 2021, Elsevier

    Taku Kobayashi

  140. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease

    Article • Nature Reviews Gastroenterology & Hepatology, August 2021, Springer Science + Business Media

    Taku Kobayashi

  141. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

    Article • Journal of Crohn s and Colitis, August 2021, Oxford University Press (OUP)

    Taku Kobayashi

  142. Can Crohn's disease patients stop anti-TNF?

    Article • Inflammatory Intestinal Diseases, August 2021, Karger Publishers

    Taku Kobayashi

  143. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial

    Article • The Lancet Gastroenterology & Hepatology, June 2021, Elsevier

    Taku Kobayashi

  144. Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group

    Article • The Lancet Gastroenterology & Hepatology, June 2021, Elsevier

    Taku Kobayashi

  145. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

    Article • Journal of Gastroenterology, May 2021, Springer Science + Business Media

    Taku Kobayashi

  146. Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis

    Article • Clinical Gastroenterology and Hepatology, May 2021, Elsevier

    Taku Kobayashi

  147. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases

    Article • United European Gastroenterology Journal, May 2021, Wiley

    Taku Kobayashi

  148. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020

    Article • Journal of Gastroenterology, April 2021, Springer Science + Business Media

    Taku Kobayashi

  149. Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis

    Article • Inflammatory Bowel Diseases, April 2021, Oxford University Press (OUP)

    Taku Kobayashi

  150. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta‐analysis

    Article • Journal of Gastroenterology and Hepatology, February 2021, Wiley

    Taku Kobayashi

  151. Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S‐methyltransferase inhibition

    Article • Journal of Gastroenterology and Hepatology, January 2021, Wiley

    Taku Kobayashi

  152. Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease

    Article • Inflammatory Bowel Diseases, January 2021, Oxford University Press (OUP)

    Taku Kobayashi

  153. Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use

    Article • Inflammatory Intestinal Diseases, January 2021, Karger Publishers

    Taku Kobayashi

  154. Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial

    Article • Journal of Crohn s and Colitis, December 2020, Oxford University Press (OUP)

    Taku Kobayashi

  155. Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial

    Article • Journal of Gastroenterology, November 2020, Springer Science + Business Media

    Taku Kobayashi

  156. Does anti‐tumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and meta‐analysis

    Article • Journal of Gastroenterology and Hepatology, October 2020, Wiley

    Taku Kobayashi

  157. Certolizumab pegol for maintenance of remission in Crohn’s disease

    Article • Cochrane Database of Systematic Reviews, October 2020, Wiley

    Taku Kobayashi

  158. Intestinal cancer in patients with Crohn's disease: A systematic review and meta‐analysis

    Article • Journal of Gastroenterology and Hepatology, September 2020, Wiley

    Taku Kobayashi

  159. The dietary practices and beliefs of people living with inactive ulcerative colitis

    Article • European Journal of Gastroenterology & Hepatology, September 2020, Wolters Kluwer Health

    Taku Kobayashi

  160. Ulcerative colitis

    Article • Nature Reviews Disease Primers, September 2020, Springer Science + Business Media

    Taku Kobayashi

  161. Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis

    Article • Journal of Gastroenterology and Hepatology, September 2020, Wiley

    Taku Kobayashi

  162. Capsule endoscopy in inflammatory bowel disease: when and how

    Article • Intestinal Research, July 2020, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  163. Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

    Article • Intestinal Research, July 2020, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  164. Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis-one more arrow in the quiver of non-invasive diagnostics. Authors’ reply

    Article • Alimentary Pharmacology & Therapeutics, June 2020, Wiley

    Taku Kobayashi

  165. Diagnosis and clinical practice guidelines for intestinal Behçet’s disease

    Article • Journal of Gastroenterology, May 2020, Springer Science + Business Media

    Dr Satoshi Tanida, Taku Kobayashi

  166. Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis

    Article • Alimentary Pharmacology & Therapeutics, May 2020, Wiley

    Taku Kobayashi

  167. Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis

    Article • Clinical Gastroenterology and Hepatology, May 2020, Elsevier

    Hirotsugu Sakamoto, Taku Kobayashi

  168. Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes

    Article • Digestive Diseases and Sciences, April 2020, Springer Science + Business Media

    Taku Kobayashi

  169. Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group

    Article • The Lancet Gastroenterology & Hepatology, April 2020, Elsevier

    Taku Kobayashi

  170. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis

    Article • Gastroenterology, February 2020, Elsevier

    Taku Kobayashi

  171. A nationwide, multi-center, retrospective study of symptomatic small bowel stricture in patients with Crohn’s disease

    Article • Journal of Gastroenterology, January 2020, Springer Science + Business Media

    Taku Kobayashi

  172. Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor-α Inhibitor Induction Therapy among Patients with Crohn’s Disease

    Article • Inflammatory Intestinal Diseases, January 2020, Karger Publishers

    Taku Kobayashi

  173. Ulcerative Colitis: Disease Burden, Impact on Daily Life, and Reluctance to Consult Medical Professionals: Results from a Japanese Internet Survey

    Article • Inflammatory Intestinal Diseases, January 2020, Karger Publishers

    Taku Kobayashi

  174. Discontinuation of Infliximab Increases the 1-Year Relapse Rate of Ulcerative Colitis in Remission - A Prospective, Multicentre, Randomised Controlled Trial

    Article • SSRN Electronic Journal, January 2020, Elsevier

    Taku Kobayashi

  175. Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis

    Article • Journal of Crohn s and Colitis, December 2019, Oxford University Press (OUP)

    Taku Kobayashi

  176. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial

    Article • Journal of Gastroenterology, December 2019, Springer Science + Business Media

    Taku Kobayashi

  177. Correction to: High-resolution melt analysis enables simple genotyping of complicated polymorphisms of codon 18 rendering the NUDT15 diplotype

    Article • Journal of Gastroenterology, November 2019, Springer Science + Business Media

    Taku Kobayashi

  178. Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice

    Article • Intestinal Research, October 2019, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  179. High-resolution melt analysis enables simple genotyping of complicated polymorphisms of codon 18 rendering the NUDT15 diplotype

    Article • Journal of Gastroenterology, October 2019, Springer Science + Business Media

    Taku Kobayashi

  180. Phosphoinositide 3-Kinase P110δ-Signaling Is Critical for Microbiota-Activated IL-10 Production by B Cells that Regulate Intestinal Inflammation

    Article • Cells, September 2019, MDPI AG

    Taku Kobayashi

  181. Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study

    Article • Journal of Gastroenterology, September 2019, Springer Science + Business Media

    Taku Kobayashi

  182. Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis

    Article • Journal of Gastroenterology and Hepatology, September 2019, Wiley

    Taku Kobayashi

  183. Certolizumab pegol for induction of remission in Crohn's disease

    Article • Cochrane Database of Systematic Reviews, August 2019, Wiley

    Taku Kobayashi

  184. Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam

    Article • PLOS One, August 2019, PLOS

    Taku Kobayashi

  185. Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis

    Article • Intestinal Research, April 2019, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  186. Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)

    Article • Journal of Gastroenterology, April 2019, Springer Science + Business Media

    Taku Kobayashi

  187. Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease

    Article • PLOS One, February 2019, PLOS

    Taku Kobayashi

  188. Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

    Article • Intestinal Research, January 2019, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  189. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More

    Article • Inflammatory Intestinal Diseases, January 2019, Karger Publishers

    Taku Kobayashi

  190. Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials

    Article • BMJ Open, January 2019, BMJ

    Taku Kobayashi

  191. Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease

    Article • Intestinal Research, October 2018, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  192. Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis With Endoscopically Normal Mucosa

    Article • Journal of Crohn s and Colitis, June 2018, Oxford University Press (OUP)

    Taku Kobayashi

  193. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study

    Article • Journal of Gastroenterology, June 2018, Springer Science + Business Media

    Taku Kobayashi

  194. Establishment of a Novel Scoring System for Colon Capsule Endoscopy to Assess the Severity of Ulcerative Colitis—Capsule Scoring of Ulcerative Colitis

    Article • Inflammatory Bowel Diseases, May 2018, Oxford University Press (OUP)

    Taku Kobayashi

  195. A Simple 1-Day Colon Capsule Endoscopy Procedure Demonstrated to be a Highly Acceptable Monitoring Tool for Ulcerative Colitis

    Article • Inflammatory Bowel Diseases, April 2018, Oxford University Press (OUP)

    Taku Kobayashi

  196. Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: The impact in steroid‐free elderly patients

    Article • Journal of Gastroenterology and Hepatology, March 2018, Wiley

    Taku Kobayashi

  197. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis

    Article • Gastroenterology, March 2018, Elsevier

    Taku Kobayashi

  198. Evidence-based clinical practice guidelines for inflammatory bowel disease

    Article • Journal of Gastroenterology, February 2018, Springer Science + Business Media

    Taku Kobayashi

  199. Th17 plasticity and its relevance to inflammatory bowel disease

    Article • Journal of Autoimmunity, February 2018, Elsevier

    Taku Kobayashi

  200. Drug Lag for Inflammatory Bowel Disease Treatments in the East and West

    Article • Inflammatory Intestinal Diseases, January 2018, Karger Publishers

    Taku Kobayashi

  201. Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease

    Article • Inflammatory Intestinal Diseases, January 2018, Karger Publishers

    Taku Kobayashi

  202. Advances in Endoscopy in Inflammatory Bowel Disease

    Article • January 2018, Springer Science + Business Media

    Taku Kobayashi

  203. Risk Factors for Mortality in <b><i>Pneumocystis jirovecii</i></b> Pneumonia in Patients with Inflammatory Bowel Disease

    Article • Inflammatory Intestinal Diseases, January 2018, Karger Publishers

    Taku Kobayashi

  204. Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries

    Article • Intestinal Research, January 2018, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  205. Certolizumab pegol for induction of remission in Crohn's disease

    Article • Cochrane Database of Systematic Reviews, December 2017, Wiley

    Taku Kobayashi

  206. Real-world Experience of Anti–tumor Necrosis Factor Therapy for Internal Fistulas in Crohnʼs Disease

    Article • Inflammatory Bowel Diseases, December 2017, Oxford University Press (OUP)

    Taku Kobayashi

  207. Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease

    Article • Journal of Gastroenterology and Hepatology, October 2017, Wiley

    Taku Kobayashi

  208. Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome

    Article • PLOS One, September 2017, PLOS

    Taku Kobayashi

  209. A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis

    Article • Journal of Gastroenterology, June 2017, Springer Science + Business Media

    Taku Kobayashi

  210. Endoscopic Indices for Ulcerative Colitis

    Article • May 2017, Springer Science + Business Media

    Taku Kobayashi

  211. Endocytoscopy can be used to assess histological healing in ulcerative colitis

    Article • Endoscopy, May 2017, Thieme Publishing Group

    Taku Kobayashi

  212. Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab

    Article • Intestinal Research, January 2017, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  213. Lipocalin 2 prevents intestinal inflammation by enhancing phagocytic bacterial clearance in macrophages

    Article • Scientific Reports, October 2016, Springer Science + Business Media

    Taku Kobayashi

  214. Involvement of herbal medicine as a cause of mesenteric phlebosclerosis: results from a large-scale nationwide survey

    Article • Journal of Gastroenterology, May 2016, Springer Science + Business Media

    Taku Kobayashi

  215. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis

    Article • Journal of Gastroenterology, July 2015, Springer Science + Business Media

    Taku Kobayashi

  216. Treatment Options after Anti-TNF Failure

    Article • January 2015, Karger Publishers

    Taku Kobayashi

  217. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: Treatment outcomes of 847 patients in clinical practice

    Article • Journal of Crohn s and Colitis, September 2014, Oxford University Press (OUP)

    Taku Kobayashi

  218. Innate PI3K p110δ Regulates Th1/Th17 Development and Microbiota-Dependent Colitis

    Article • The Journal of Immunology, April 2014, Oxford University Press (OUP)

    Taku Kobayashi

  219. Modified bowel preparation regimen for use in second-generation colon capsule endoscopy in patients with ulcerative colitis

    Article • Digestive Endoscopy, March 2014, Wiley

    Taku Kobayashi

  220. Which makes patients happier, surgery or anti-TNF therapy?

    Article • Nature Reviews Gastroenterology & Hepatology, March 2014, Springer Science + Business Media

    Taku Kobayashi

  221. NFIL3-Deficient Mice Develop Microbiota-Dependent, IL-12/23–Driven Spontaneous Colitis

    Article • The Journal of Immunology, February 2014, Oxford University Press (OUP)

    Taku Kobayashi

  222. Carbon Monoxide and Heme Oxygenase-1 Prevent Intestinal Inflammation in Mice by Promoting Bacterial Clearance

    Article • Gastroenterology, April 2013, Elsevier

    Taku Kobayashi

  223. Lectin-based Immunoassay for Aberrant IgG Glycosylation as the Biomarker for Crohnʼs Disease

    Article • Inflammatory Bowel Diseases, February 2013, Oxford University Press (OUP)

    Taku Kobayashi

  224. Inducible colitis-associated glycome capable of stimulating the proliferation of memory CD4+ T cells

    Article • Journal of Experimental Medicine, December 2012, Rockefeller University Press

    Taku Kobayashi

  225. In Vitro and In Vivo Evaluation of a Water-in-Oil Microemulsion System for Enhanced Peptide Intestinal Delivery

    Article • The AAPS Journal, November 2012, Springer Science + Business Media

    Taku Kobayashi

  226. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis

    Article • Inflammatory Bowel Diseases, November 2012, Wolters Kluwer Health

    Dr Shinya Matsuzaki, Taku Kobayashi

  227. IL-10 Regulates Il12b Expression via Histone Deacetylation: Implications for Intestinal Macrophage Homeostasis

    Article • The Journal of Immunology, August 2012, Oxford University Press (OUP)

    Taku Kobayashi

  228. A Cell Permeable Peptide Inhibitor of NFAT Inhibits Macrophage Cytokine Expression and Ameliorates Experimental Colitis

    Article • PLOS One, March 2012, PLOS

    Taku Kobayashi

  229. Correlation between endocytoscopy and conventional histopathology in microstructural features of ulcerative colitis

    Article • Journal of Gastroenterology, July 2011, Springer Science + Business Media

    Taku Kobayashi

  230. An Anti-Inflammatory Role for Carbon Monoxide and Heme Oxygenase-1 in Chronic Th2-Mediated Murine Colitis

    Article • The Journal of Immunology, May 2011, Oxford University Press (OUP)

    Taku Kobayashi

  231. A case of thyroid-type papillary carcinoma derived from ovarian mature cystic teratoma, resected by laparoscopic surgery

    Article • Asian Journal of Endoscopic Surgery, April 2011, Wiley

    Taku Kobayashi

  232. NFIL3 Is a Regulator of IL-12 p40 in Macrophages and Mucosal Immunity

    Article • The Journal of Immunology, April 2011, Oxford University Press (OUP)

    Taku Kobayashi

  233. Characterization of an Interferon-stimulated Response Element (ISRE) in the Il23a Promoter

    Article • Journal of Biological Chemistry, January 2011, Elsevier

    Taku Kobayashi

  234. Altered Macrophage Function Contributes to Colitis in Mice Defective in the Phosphoinositide-3 Kinase Subunit p110δ

    Article • Gastroenterology, November 2010, Elsevier

    Taku Kobayashi

  235. In vivo visualization of trophozoites in patients with amoebic colitis by using a newly developed endocytoscope

    Article • Gastrointestinal Endoscopy, September 2010, Elsevier

    Taku Kobayashi

  236. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis

    Article • Journal of Gastroenterology, July 2010, Springer Science + Business Media

    Taku Kobayashi

  237. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients

    Article • Journal of Gastroenterology, April 2010, Springer Science + Business Media

    Taku Kobayashi

  238. Cutting Edge: IFN-γ Is a Negative Regulator of IL-23 in Murine Macrophages and Experimental Colitis

    Article • The Journal of Immunology, April 2010, Oxford University Press (OUP)

    Taku Kobayashi

  239. Monocyte Chemoattractant Protein-1 Contributes to Gut Homeostasis and Intestinal Inflammation by Composition of IL-10–Producing Regulatory Macrophage Subset

    Article • The Journal of Immunology, March 2010, Oxford University Press (OUP)

    Taku Kobayashi

  240. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease

    Article • Inflammatory Bowel Diseases, October 2009, Oxford University Press (OUP)

    Taku Kobayashi

  241. Human CD14+ Macrophages in Intestinal Lamina Propria Exhibit Potent Antigen-Presenting Ability

    Article • The Journal of Immunology, August 2009, Oxford University Press (OUP)

    Taku Kobayashi

  242. Dietary Histidine Ameliorates Murine Colitis by Inhibition of Proinflammatory Cytokine Production From Macrophages

    Article • Gastroenterology, February 2009, Elsevier

    Taku Kobayashi

  243. I. Concept, Definition and Epidemiology of Inflammatory Bowel Diseases

    Article • Nihon Naika Gakkai Zasshi, January 2009, Japanese Society of Internal Medicine

    Taku Kobayashi

  244. Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice

    Article • Inflammatory Bowel Diseases, November 2008, Oxford University Press (OUP)

    Taku Kobayashi

  245. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease

    Article • Gut, July 2008, BMJ

    Taku Kobayashi

  246. Unique CD14+ intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-γ axis

    Article • Journal of Clinical Investigation, May 2008, American Society for Clinical Investigation

    Taku Kobayashi

  247. Lamina Propria c-kit+ Immune Precursors Reside in Human Adult Intestine and Differentiate Into Natural Killer Cells

    Article • Gastroenterology, August 2007, Elsevier

    Taku Kobayashi

  248. Exclusive increase of CX3CR1+CD28−CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes

    Article • Inflammatory Bowel Diseases, July 2007, Oxford University Press (OUP)

    Taku Kobayashi

  249. Monozygotic twins concordant for intestinal Behçet’s disease

    Article • Journal of Gastroenterology, May 2005, Springer Science + Business Media

    Taku Kobayashi

  250. Gastrin and Helicobacter pylori in Low-grade MALT Lymphoma Patients

    Article • Scandinavian Journal of Gastroenterology, January 2002, Taylor & Francis

    Taku Kobayashi

  251. Lowering barometric pressure aggravates mechanical allodynia and hyperalgesia in a rat model of neuropathic pain

    Article • Neuroscience Letters, April 1999, Elsevier

    Taku Kobayashi